Xia et al. Upadacitinib in refractory Behcets. Open label, 8 patients. Follow-up 4-14 months. Lower disease activity 2.5 vs 1.5. Lower pred, 11.9 vs 8.1. @RheumNow #ACR24 Abstr#2515 https://t.co/ZXsJkNRlTm https://t.co/S8LhpqZ8X3
Links:
Upadacitinib for Refractory Behçet’s Syndrome: A Multi-center, Prospective, Ope…
https://acrabstracts.org/abstract/upadacitinib-for-refractory-behcets-syndrome-…
18-11-2024